Eighty-six SAE patients declared infectious and noninfectious
| Toxicity . | FCCam . | FCR . |
|---|---|---|
| Infectious | 10 febrile neutropenia of undetermined origin 1 staphylococcal sepsis with septic shock 1 disseminated mucormycosis 2 Pneumocystis jiroveci pneumonia 1 Clostridium difficile colitis 2 bronchitis 1 Pseudomonas aeruginosa sepsis 2 bronchopulmonary aspergillosis 1 BK virus infection 1 adenovirus infection 4 pneumonia without infectious identification 2 meningitis due to Pneumococcus and Listeria 2 EBV-associated lymphoproliferative disorder 1 CMV infection | 9 febrile neutropenia of undetermined origin 1 pure red cell aplasia (due to parvovirus B19) 1 pneumococcal pneumonia 1 erysipelas 1 bronchitis |
| Noninfectious | 2 non-Hodgkin lymphoma (1 due to EBV) 1 diarrhea 1 cerebrovascular accident 1 tumor lysis syndrome 1 cardiac failure 1 pulmonary embolism 2 cytokine release syndrome 1 gastrointestinal stromal tumor 1 obstructive cholelithiasis 1 acute febrile neutrophilic dermatosis 1 respiratory failure 1 skin necrosis 2 hematophagic histiocytosis syndrome | 1 acute pulmonary edema 1 tumor lysis syndrome 1 renal cancer 1 metastatic colon cancer 1 pleural effusion 1 generalized rash 1 cytokine release syndrome 1 gastric ulcer |
| Late toxicities* | 3 febrile neutropenia of undetermined origin 3 pneumonias (1 due to Legionella) 1 pneumococcal sepsis 1 bronchitis 1 toxoplasma eye infection 1 pyelonephritis 1 herpes zoster, multidermatomal 1 non-Hodgkin lymphoma 1 acrodermatitis 1 subdural hematoma 1 autoimmune thrombocytopenia | 1 bile duct cancer 1 myelodysplastic syndrome 1 transient ischemic attack |
| Toxicity . | FCCam . | FCR . |
|---|---|---|
| Infectious | 10 febrile neutropenia of undetermined origin 1 staphylococcal sepsis with septic shock 1 disseminated mucormycosis 2 Pneumocystis jiroveci pneumonia 1 Clostridium difficile colitis 2 bronchitis 1 Pseudomonas aeruginosa sepsis 2 bronchopulmonary aspergillosis 1 BK virus infection 1 adenovirus infection 4 pneumonia without infectious identification 2 meningitis due to Pneumococcus and Listeria 2 EBV-associated lymphoproliferative disorder 1 CMV infection | 9 febrile neutropenia of undetermined origin 1 pure red cell aplasia (due to parvovirus B19) 1 pneumococcal pneumonia 1 erysipelas 1 bronchitis |
| Noninfectious | 2 non-Hodgkin lymphoma (1 due to EBV) 1 diarrhea 1 cerebrovascular accident 1 tumor lysis syndrome 1 cardiac failure 1 pulmonary embolism 2 cytokine release syndrome 1 gastrointestinal stromal tumor 1 obstructive cholelithiasis 1 acute febrile neutrophilic dermatosis 1 respiratory failure 1 skin necrosis 2 hematophagic histiocytosis syndrome | 1 acute pulmonary edema 1 tumor lysis syndrome 1 renal cancer 1 metastatic colon cancer 1 pleural effusion 1 generalized rash 1 cytokine release syndrome 1 gastric ulcer |
| Late toxicities* | 3 febrile neutropenia of undetermined origin 3 pneumonias (1 due to Legionella) 1 pneumococcal sepsis 1 bronchitis 1 toxoplasma eye infection 1 pyelonephritis 1 herpes zoster, multidermatomal 1 non-Hodgkin lymphoma 1 acrodermatitis 1 subdural hematoma 1 autoimmune thrombocytopenia | 1 bile duct cancer 1 myelodysplastic syndrome 1 transient ischemic attack |
Late toxicities occurred after the final evaluation (3 months after the end of treatment or at the ninth month when treatment was prematurely stopped).